NasdaqCM - Delayed Quote USD

Marker Therapeutics, Inc. (MRKR)

4.2900 -0.1900 (-4.24%)
At close: April 26 at 4:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MRKR

Recent News: MRKR

View More
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
GlobeNewswire 18 days ago
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
GlobeNewswire last month
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GlobeNewswire last month
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
GlobeNewswire 3 months ago
Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization
Benzinga 3 months ago
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
GlobeNewswire 3 months ago
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
GlobeNewswire 4 months ago
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse

Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
GlobeNewswire 4 months ago
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
GlobeNewswire 5 months ago
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Simply Wall St. 6 months ago
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire 7 months ago
Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance

Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
GuruFocus.com 7 months ago
View More

Related Tickers

AEZS Aeterna Zentaris Inc.
1.9562
-1.70%
 
SLNO Soleno Therapeutics, Inc.
37.89
+1.47%
 
LPTX Leap Therapeutics, Inc.
3.2500
+2.52%
 
ARTL Artelo Biosciences, Inc.
1.3399
+0.74%
 
ARDS Aridis Pharmaceuticals, Inc.
0.0650
0.00%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
APRE Aprea Therapeutics, Inc.
5.20
-2.07%
 
SNPX Synaptogenix, Inc.
4.5300
+2.72%
 
ALDX Aldeyra Therapeutics, Inc.
3.9300
-0.25%
 
ENGNW enGene Holdings Inc.
4.0202
+3.35%